



## Correction to: the efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial

Xia Liu<sup>1</sup> · Xiaomei Li<sup>2</sup> · Xiangpei Li<sup>2</sup> · Zhijun Li<sup>3</sup> · Dongbao Zhao<sup>4</sup> · Shengyun Liu<sup>5</sup> · Miaojia Zhang<sup>6</sup> · Fengxiao Zhang<sup>7</sup> · Ping Zhu<sup>8</sup> · Jinwei Chen<sup>9</sup> · Wei Wei<sup>10</sup> · Bing Lin<sup>1</sup> · Yingbo Zhou<sup>2</sup> · Jing Chen<sup>3</sup> · Yafei Pang<sup>4</sup> · Lei Zhang<sup>5</sup> · Xiaoxuan Sun<sup>6</sup> · Zhibo Yu<sup>7</sup> · Yun Jia<sup>8</sup> · Jia Wang<sup>9</sup> · Wenwen Sun<sup>10</sup> · Frank Chiu<sup>11</sup> · Liping Pang<sup>11</sup> · Guochun Wang<sup>1</sup>

Published online: 3 December 2018

© International League of Associations for Rheumatology (ILAR) 2018

### Correction to: Clinical Rheumatology

<https://doi.org/10.1007/s10067-018-4315-8>

The authors regret that the Fig. 1 in the original version of this article contained an error. In the left column, 211 cases in the TGP group should be followed up for 8 weeks before 12 weeks. The correct figure is shown as follows:

---

The online version of the original article can be found at <https://doi.org/10.1007/s10067-018-4315-8>

---

✉ Guochun Wang  
guochunwang@hotmail.com

<sup>1</sup> Department of Rheumatology, China-Japan Friendship Hospital, No.2, East Yinghua Road, Chaoyang District, Beijing 100029, China

<sup>2</sup> Department of Rheumatology and Immunology, Anhui Provincial Hospital, Hefei, Anhui, China

<sup>3</sup> Department of Rheumatology and Immunology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China

<sup>4</sup> Department of Rheumatology and Immunology, Changhai Hospital, Shanghai, China

<sup>5</sup> Department of Rheumatology and Immunology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

<sup>6</sup> Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

<sup>7</sup> Department of Rheumatology, Hebei General Hospital, Shijiazhuang, Hebei, China


<sup>8</sup> Department of Clinical Immunology, Xi-Jing Hospital, Xi'an, Shaanxi, China

<sup>9</sup> Division of Rheumatoid Immunology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China

<sup>10</sup> Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, China

<sup>11</sup> Boon Pharmaceutical Research Ltd., 45 Topanga, Irvine, CA 92602, USA

**Fig. 1** Flow chart of the study of TGP for treatment of primary Sjögren's syndrome. A total of 320 patients were assessed, and 314 patients were randomized: 211 to TGP and 103 to placebo group. At week 24, 170 patients in TGP and 88 patients in placebo group completed the study



**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.